GLP-2R

GLP-2R Research Overview

Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors, producing average weight loss of about 20 percent at the top amount in trials. It is sold as Mounjaro for diabetes and Zepbound for weight management and sleep apnea.

Also known as: Mounjaro, Zepbound, LY3298176

Background

Tirzepatide is a single 39 amino acid peptide built on the GIP hormone backbone and tuned to activate both the GIP and GLP-1 receptors. Eli Lilly developed it with a fatty diacid side chain for albumin binding, which gives it a half-life of about five days and once-weekly administration parameters. It reached the market as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in late 2023, later adding an indication for obstructive sleep apnea in people with obesity.

The headline numbers come from SURMOUNT-1: adults with obesity but not diabetes lost an average of about 15, 19.5 and 20.9 percent of body weight at the 5, 10 and 15 mg doses over 72 weeks, against about 3 percent on placebo. In the head-to-head SURMOUNT-5 trial against semaglutide 2.4 mg, tirzepatide 15 mg produced roughly 20 percent loss versus about 14 percent, which makes it the strongest approved option as of now.

As with semaglutide, the vials sold through research suppliers are not the branded product. Lilly does sell single-amount Zepbound vials through its own direct-to-consumer channel in the US, and those are legitimate. Grey-market lyophilized tirzepatide is a separate thing with no guaranteed purity, and underdosed or mislabeled vials are a documented problem in that market.

Mechanistic Profile

Tirzepatide hits two incretin receptors at once. The GLP-1 side does what semaglutide does: it boosts glucose-dependent insulin release, slows gastric emptying and dampens hunger signaling in the brain. The GIP side is less well understood but appears to add to appetite suppression, improve how fat tissue handles lipids, and may soften some of the nausea that GLP-1 activation alone produces. The molecule is actually biased toward the GIP receptor and is a weaker GLP-1 agonist than semaglutide molecule for molecule, yet the combination produces larger weight loss, which is the main argument that dual agonism is doing something real rather than just being a stronger GLP-1 drug.

Reported Research Findings

• (human RCT)

• Beat semaglutide 2.4 mg head to head, about 20 percent versus 14 percent weight loss at 72 weeks (SURMOUNT-5). (human RCT)

• Greater HbA1c reduction than semaglutide 1 mg in type 2 diabetes (SURPASS-2). (human RCT)

• Cut the apnea-hypopnea index by roughly 25 to 30 events per hour in obesity-related sleep apnea (SURMOUNT-OSA), leading to an FDA indication. (clinical (approved drug))

• Reduced progression from prediabetes to type 2 diabetes by over 90 percent across three years of treatment (SURMOUNT-1 extension). (human RCT)

Analytical Validation, Formulation and Storage

• Purity: 99% or higher as verified by HPLC, with a third-party certificate of analysis available per batch.

• Formulation: lyophilised (freeze-dried) powder in a sterile sealed glass vial, to be reconstituted with an appropriate solvent for laboratory use.

• Reported half-life: About 5 days (roughly 117 hours).

• Storage: keep lyophilised material cool, dark and dry (long-term at or below -20 °C). Store reconstituted solutions refrigerated, avoid repeated freeze-thaw cycles and use within laboratory-defined windows.

Selected Literature

• Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.

• Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.

• Tirzepatide versus semaglutide for weight loss in adults with obesity without diabetes (SURMOUNT-5). New England Journal of Medicine, 2025.

• Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). New England Journal of Medicine, 2024.

Cloud Aminos supplies GLP-2R as a high-purity research material intended strictly for controlled laboratory use in vitro or in established animal models. This compound is not approved as a drug, diagnostic or dietary ingredient and is not manufactured, packaged or marketed for human consumption, self-experimentation, clinical application or any use outside properly designed and ethically approved research protocols.